Recursion Pharmaceuticals Inc. (RXRX)
RXRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.83
-4.36% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$74.7M
+26.9% on 2024
Net income · 2025
-$644.8M
-863.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | RXRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001601830 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $74.7M |
| Net income | -$644.8M |
| Operating income | -$648.1M |
| Net margin | -863.4% |
| Operating margin | -867.9% |
| Revenue growth | +26.9% |
| Cash | $743.3M |
| Total assets | $1.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 27.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-25 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 982 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.0% |
| 1 month | +14.7% |
| 3 months | +23.0% |
| Year to date | -9.2% |
| 1 year | -32.8% |
| From 52-week high | -45.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc. | $8.07 | -3.47% | $2.1B |
| VCEL | Vericel Corporation | $40.30 | -0.79% | $2.1B |
| ALVO | Alvotech | $5.38 | -2.18% | $2.1B |
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
| ADMA | ADMA Biologics Inc | $10.31 | +1.28% | $2.3B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| BEAM | Beam Therapeutics Inc. | $24.43 | -2.79% | $2.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier